Buy Us a Cup of Coffee

AscellaHealth & Audaire Health Launch Hemophilia Management Program

AscellaHealth
Program can contain prescription costs by 12-25% and give patients the support they need to use medications consistently and correctly.

BERWYN, PAAscellaHealth, a specialty pharmacy benefit manager (SPBM), serving commercial, Medicare and Medicaid segments, is teaming up with Audaire Health to offer an all-encompassing hemophilia management program.

With AscellaHealth’s customized, trusted and transparent network of specialty pharmacy partners and Audaire Health’s HIPAA compliant, patent-pending technology, this innovative program provides pharmacy network design, appropriate utilization management and clinical interventions based on active patient management.

“Together with Audaire Health, AscellaHealth is transforming hemophilia management, offering a groundbreaking approach that allows payers to contain the costs of expensive drugs to treat hemophilia – as much as $50,000 a dose – with some patients treated prophylactically for the duration of therapy at a cost of $300,000 to millions per year,” says Dea Belazi, president and CEO, AscellaHealth. “This program could not have been introduced at a better time in light of the recent approval of novel agents such Hemlibra for non-inhibitors, essentially doubling the price of therapy. Now more than ever, payers need to be prepared with the type of effective formulary strategies and utilization management/clinical programs that are exemplified with our new solution.”

READ:  Trump Administration Issues Guidance to Ensure States Have a Plan in Place to Safely Reopen Nursing Homes

Belazi explains that over the past decade, factor utilization has increased substantially among hemophilia A and B patients, with payers assuming most of the additional costs. In fact, hemophilia was the number one stop-loss claim item in the last three years. He projects that payers will continue to struggle with the challenges of managing the cost of novel drugs with a high price tag and a short history of clinical use.

“Our new program answers these challenges, as evidenced by typical client cost savings which are quite compelling,” says Belazi, pointing to savings of $1.5M on the specialty spend for a third-party administrator in the first year and a reduced drug spend of $1M for 20 patients as reported by a broker. One hospital reduced its specialty spend by 30% in the first year.

READ:  Trump Administration Issues Guidance to Ensure States Have a Plan in Place to Safely Reopen Nursing Homes

Andrew Berg, CEO of Audaire Health, emphasizes the companies’ shared commitment to delivering customized clinical management, transparency and accountability.

“We are offering patients a simple way of logging infusions and bleeds,” he explains. “Our technology combines patient reported utilization data, physician performance data with pharmacy dispensation data that spans assay, lot and expiration into a single platform. This provides care teams with real-time access to infusion logs and bleed alerts, allowing for quick interventions if necessary.”

To learn more about this innovative program, contact Michael Baldzicki, executive vice president, growth and strategy, AscellaHealth, via email at [email protected].

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee